After 36 years of being in business, Immunogen (NASDAQ: IMGN) has yet to make a profit. Unfortunately, the biotech still isn’t close to reaching break-even status.
Immunogen stock has lost over half of its value during the last 12 months. Despite the seemingly bleak situation, there are some reasons for cautious optimism about the biotech — along with some worrisome factors. These three charts highlight the potential risks and rewards for investors considering buying Immunogen stock.
Image source: Getty Images.